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Abstract
A recurring challenge for brain pathologists is to diagnose whether a brain malignancy is a
primary tumor or a metastasis from some other tissue. The accurate diagnosis of brain
malignancies is essential for selection of proper treatment. MicroRNAs are a class of small
non-codingRNAspeciesthatregulategeneexpression;manyexhibittissue-speciﬁcexpres-
sion and are misregulated in cancer. Using microRNA expression proﬁling, we found that
hsa-miR-92b and hsa-miR-9/hsa-miR-9* are over-expressed, speciﬁcally in brain primary
tumors, as compared to primary tumors from other tissues and their metastases to the brain.
By considering the expression of only these two microRNAs, it is possible to distinguish
between primary and metastatic brain tumors with very high accuracy. These microRNAs
thus represent excellent biomarkers for brain primary tumors. Previous reports have found
that hsa-miR-92b and hsa-miR-9/hsa-miR-9* are expressed more strongly in developing
neurons and brain than in adult brain. Thus, their speciﬁc over-expression in brain primary
tumorssupportsafunctionalroleforthesemicroRNAsoralinkbetweenneuronalstemcells
and brain tumorigenesis.
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INTRODUCTION
A current effort of cancer research is to discover biomarkers that
can improve cancer diagnosis in a clinical setting. Speciﬁcally, the
pathological characterization of brain malignancies remains a
diagnostic challenge. Despite the advent of various high through-
put genomic-level technologies, which allow multiple DNA
sequences, mRNAs or proteins to be evaluated simultaneously and
systematically, these have had little impact on clinical procedures.
Recently, however, there has been a paradigm shift in our under-
standing of genome expression, with the realization that there
exists a class of small non-coding RNA species, known as micro-
RNAs (miRNAs or miRs), which have critical functions in many
biological processes (27). Although the total number of micro-
RNAs remains controversial (2, 3, 18) and the roles of speciﬁc
microRNAs are only beginning to be deﬁned, high throughput
microRNA expression analyses indicate that these species repre-
sent promising candidates for clinical tumor cell markers (6).
Ingeneral,microRNAsareregulatedandtranscribedsimilarlyto
protein coding genes. Subsequent microRNA biogenesis involves
discrete processing and transport steps, whereby the active moiety
of 20–22 nucleotides is excised from a longer RNA precursor that
exhibits speciﬁc hairpin structure. Finally, these 20–22 nucleotides
are incorporated into a composite machinery, termed the RNA-
induced silencing complex, which promotes partial duplex forma-
tion between the short RNA and the 3′ untranslated regions of
targeted transcripts, resulting typically in mammals in translational
silencing (27). Systematic, high throughput microRNA expression
analyses of many diverse tumors indicate that tumors display
microRNA expression proﬁles that are signiﬁcantly different from
those of normal tissue, and moreover, these microRNA proﬁles are
extremely informative with respect to developmental lineage and
differentiation state of the tumor (6). Studies have suggested that,
unlike with mRNA expression, a modest number of ~200 micro-
RNAs might be sufﬁcient to classify human cancers (15).Accord-
ing to emerging studies that reveal an unexpected target speciﬁcity
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smaller number of microRNAs may serve to identify tumors and to
deﬁne clinically important tumor characteristics. In a recent study
(23), we used microRNA microarray data and developed general
classiﬁcation algorithms for a range of tissues. In that study, we
also identiﬁed microRNAs that can identify brain tumors from a
subset of non-epithelial tumors.
Differentiation between primary and metastatic tumors in the
brain is often encountered in pathological practice, as metastatic
tumors to the brain are quite frequent.The most common tumors to
metastasize to the brain originate in the lung(10), breast (30) and
skin (melanomas) (5, 7, 22); their respective contributions to all
central nervous system (CNS) metastases are 30%, 20% and 10%.
Although rare, choriocarcinoma disseminates to the brain with a
particularly high frequency (26). In autopsy studies, 24% of cancer
patients exhibited metastatic tumors in the CNS (19). Indeed, sur-
gical pathologists are regularly presented with specimens from
patients with a history of systemic neoplasia but with ﬁndings that
suggest a primary intracranial tumor (19).
Here, we directly compare brain tumors to a wide range of epi-
thelial tumors and metastases to the brain. Using microarray data,
we found that elevated expression of just two microRNAs, hsa-
miR-92b and hsa-miR-9*, is sufﬁcient to distinguish brain primary
tumors from tumors derived from non-brain tissues, and most sig-
niﬁcantly for diagnostic purposes, from metastases located in the
brain. We translated this assay to a qRT-PCR platform, using addi-
tional samples as a training set to develop a classiﬁer.Validating on
an independent set of test samples, we found that the simple com-
bination of hsa-miR-92b and hsa-miR-9 (or hsa-miR-9*) can iden-
tify brain metastases from brain primary tumors with sensitivity of
88% and speciﬁcity of 100%.Thus, economical and relatively easy
evaluation of hsa-miR-92b and hsa-miR-9/9* expression, which
can be performed robustly using either fresh frozen or ﬁxed mate-
rials in the clinical setting (33), reveals whether neoplastic tissue
excised from the brain is brain-derived or represents a metastasis
from another tissue. Hsa-miR-92b and hsa-miR-9/9* were identi-
ﬁed previously to be over-expressed in developing brain and
neuronal stem cells compared to adult brain, and thus have been
implicated as players in human nervous system development (12,
13, 32, 34). Taken together, the expression data concerning hsa-
miR-92b and hsa-miR-9/9* suggest a connection between deregu-
lation of microRNAs, pluripotency and tumorigenesis (4, 31).
MATERIALS AND METHODS
Tumor samples
A total of 285 formalin-ﬁxed parafﬁn-embedded (FFPE) tumor
samples were obtained from several sources (Sheba Medical
Center, Tel-Hashomer, Israel; Soroka University Medical Center,
Beer-Sheva, Israel; Beilinson Hospital, Rabin Medical Center,
Petah-Tikva, Israel;ABS Inc., Wilmington, DE;TelAviv Sourasky
Medical Center,TelAviv, Israel).The study protocol was approved
by the Research Ethics Board of each of the contributing institutes.
Each of the FFPE samples was evaluated by a pathologist for histo-
logical type, grade and tumor percentage based on hematoxylin-
eosin-stained slides, performed on the ﬁrst and/or last sections of
thesample.Thetumorcontentwas50%in92%ofthesamples.A
total of 252 of the samples were proﬁled by microRNA microarray.
Fourteen of these samples and 33 additional samples were proﬁled
by qRT-PCR. Histological classiﬁcation of the study samples is
summarized in Table 1 and listed in detail inTable S1 andTable S2
in Supplementary Information online.
RNA extraction
Total RNA was isolated from 7 to 10 10 mm-thick tissue sections
per case using the miRdictor™ extraction protocol developed at
Rosetta Genomics (Rehovot, Israel). Brieﬂy, the sample was incu-
bated a few times in xylene at 57°C to remove excess parafﬁn,
and then was washed several times with ethanol. Proteins were
degraded by incubating the sample in a proteinase K solution at
45°C for a few hours. The RNA was extracted using acid phenol/
chloroform and then precipitated using ethanol; DNAses were
introduced to digest DNA. Total RNA quantity and quality was
measured by Nanodrop™ ND-1000 (NanoDrop Technologies,
Wilmington, DE).
Figures S1 and S2 in Supplementary Information online demon-
strate the reliability of the RNA extraction protocols.
miRdicator™ array platform
Custom microRNA microarrays were prepared as described previ-
ously (21). Brieﬂy on Slide E coated microarray slides (Schott
Nexterion, Mainz, Germany) ~650 DNA oligonucleotide probes
representing microRNAs (Sanger database version 9 and addi-
tional microRNAs predicted and validated by Rosetta Genomics)
were spotted in triplicate using the BioRobotics MicroGrid II
microarrater (Genomic Solutions,AnnArbor, MI) according to the
manufacturer’s directions. Fifty-four negative control probes were
designed using the sense sequences of different microRNAs. Two
types of positive control were included in the experimental design:
(i)syntheticsmallRNAswerespikedintoeachRNAsamplebefore
labeling to verify labeling efﬁciency; and (ii) probes for abundant
small RNAs were spotted on the miRdicator™ array to validate
RNA quality.
A total of 3.5 mg of total RNA were labeled by ligation of an
RNA-linker, p-rCrU-Cy/dye (Dharmacon, Lafayette, CO; Cy3 or
Cy5) to the 3′ end. Slides were incubated with the labeled RNA for
12–16 hat42°Candthenwashedtwice.Arrayswerescannedusing
Agilent DNA Microarray Scanner Bundle (Agilent Technologies,
Santa Clara, CA) at a resolution of 10 mm at 100% power. Array
images were analyzed using SpotReader software (Niles Scientiﬁc,
Portola Valley, CA). Figure S3 demonstrates the reproducibility,
sensitivity and speciﬁcity of the miRdicator™ microRNA micro-
array platform.
Microarray spots were combined and signals normalized as
described previously (21).Triplicate spots were combined into one
signal by taking the logarithmic mean of the reliable spots.All data
were log-transformed and the analysis was performed in log-space.
A reference data vector for normalization, R, was calculated by
taking the median expression level for each probe across all
samples. For each sample k with data vector Sk, a 2nd degree
polynomial Fk was found so as to provide the best ﬁt between the
sample data and the reference data, such that R ª Fk(Sk). Remote
data points (“outliers”) were not used for ﬁtting the polynomials F.
For each probe in the sample (element Si
k in the vector Sk), the
normalized value (in log-space) Mi
k is calculated from the initial
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n Samples in microarray data—
by category
Detail
15 Brain primary tumors Anaplastic astrocytoma (2), anaplastic oligodendroglioma (1), glioblastoma multiforme (7), low grade
astrocytoma (3), oligodendroglioma (2)
187 Other primary tumors Adipose liposarcoma (4),
Bladder (1 transitional cell carcinoma),
Breast (3 including 1 inﬁltrating lobular carcinoma),
Cervix (3 adenocarcinoma, 2 squamous cell carcinoma),
Colon (4 adenocarcinoma),
Endometrium (7 adenocarcinoma),
Esophagus (2 adenocarcinoma, 5 squamous cell carcinoma),
Esophagus-stomach (7 adenocarcinoma),
Gallbladder (3 adenocarcinoma),
Kidney (6 renal cell carcinoma),
Larynx (4 squamous cell carcinoma),
Liver (2 hepatocellular carcinoma),
Lung (7 neuroendocrine carcinoid, 1 neuroendocrine large cell, 1 neuroendocrine; mix small cell-large cell,
7 neuroendocrine small cell, 8 non-small cell adenocarcinoma, 3 non-small large cell carcinoma, 8
non-small squamous cell carcinoma, 7 pleura mesothelioma),
Lymphocytes (10 Hodgkin’s lymphoma),
Melanocytes (3 malignant melanoma),
Meninges (8 meningioma, 1 atypical meningioma),
Mouth (5 squamous cell carcinoma),
Nose (5 squamous cell carcinoma),
Ovary (7 serous papillary cancer),
Pancreas (3 adenocarcinoma, 2 ductal adenocarcinoma, 2 exocrine adenocarcinoma),
Prostate (7 samples including 2 BPH samples)
Small intestine (7 stromal tumor, 1 adenocarcinoma),
Stomach adenocarcinoma (5),
Testis seminoma (3),
Thymus thymoma (3 type b2, 4 type b3),
Thyroid (4 carcinoma, 3 papillary carcinoma, 1 papillary tall cell carcinoma),
Tongue (10 squamous cell carcinoma),
50 Metastases in brain Bladder (1 transitional cell carcinoma),
Breast (4 adenocarcinoma, 9 inﬁltrating ductal carcinoma),
Colon (5 adenocarcinoma),
Endometrial tumor (1),
Kidney (2 clear cell carcinoma, 1 renal cell carcinoma),
Lung (10 including 1 carcinoma, 1 neuroendocrine small-cell carcinoma, 6 non-small cell adenocarcinoma,
1 non-small squamous cell carcinoma),
Melanocytes (4 melanoma, 2 malignant melanoma),
Unknown (3 carcinoma, 5 adenocarcinoma, 1 small cell carcinoma, 2 sarcoma),
n Additional samples in qRT-PCR
validation set
Detail
15 Brain primary tumors Anaplastic oligodendroglioma (1), astrocytoma (5), glioblastoma multiforme (2), oligodendroglioma (7)
8 Other primary tumors Bladder (1 transitional cell carcinoma),
Kidney (1 renal cell carcinoma),
Liver (1 hepatocellular carcinoma),
Lung (1 non-small cell adenocarcinoma, 1 pleura mesothelioma),
Ovary (1 adenocarcinoma),
Pancreas (1 neuroendocrine carcinoma),
Thymus thymoma (1 type b2)
10 Metastases in brain Breast (2 adenocarcinoma),
Kidney (3 adenocarcinoma),
Lung (1 non-small cell adenocarcinoma, 2 non-small squamous cell carcinoma),
Ovary (2 adenocarcinoma)
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k by transforming it with the polynomial function Fk,s o
that MF S i
kk
i
k = () . Data is translated back to linear-space by taking
the exponent. Henceforth, the expression level or signal of a
microRNA refers to the normalized value. Values of normalized
expression for each sample for the microRNAs examined in the
study are available in Table S1 in Supplementary Information
online.
qRT-PCR
One mg of total RNA was subjected to polyadenylation reaction as
described before (25). Brieﬂy, RNA was incubated in the presence
of poly (A) polymerase (Takara-2180A), MnCl2 andATP for 1 h at
37°C. Reverse transcription was performed on the polyadenylated
product. An oligo-dT primer harboring a consensus sequence
(complementary to the reverse primer) was used for reverse tran-
scription reaction.The primer is ﬁrst annealed to the polyA–RNA
and then subjected to a reverse transcription reaction of Super-
Script II RT (Invitrogen). The cDNA was then ampliﬁed by
real-time PCR reaction, using a miRNA-speciﬁc forward primer,
TaqMan probe and universal reverse primer. The reactions were
incubated for 10 minutes at 95°C, followed by 42 cycles of 95°C
for 15 s and 60°C for 1 minute in Applied Biosystems 7500 ther-
mocyclers. Values of cycle to pass threshold (Ct), representing
inverse log2 expression levels, are listed inTable S2 in Supplemen-
tary Information online. Normalizing the Ct values (per sample) by
the Ct of either U6 snRNA(28), the Ct of hsa-miR-24, or their
averageCt,shiftedatmostonesamplefromeachsideinthetest-set
classiﬁcation predictions.
Data analysis and statistics
InordertoidentifymicroRNAsignaturesthatcanbeusedtodiffer-
entiate primary brain tumors from brain metastases, we compared
thebrainprimarytumorsamplestootherprimarytumorsandtothe
brain metastases using statistical tests (see Table 2). P-values were
calculated using a two-sided t-test on the log-transformed normal-
ized signal. After adjustment for false detection rate or the more
strict Bonferroni correction (multiply each P-value by the number
of microRNAs tested, ~1000), most P-values remain highly sig-
niﬁcant (Table 2 lists unadjusted P-values; P-values are mostly
below 1e-8). The t-test is designed to identify differences in the
distribution mean, but is not an ideal tool to develop classiﬁers.We
used the area under curve (AUC) of the response operating charac-
teristic (ROC) curve to identify microRNA and microRNA com-
binations that could be used to classify samples accurately (see
Figure S5).Thereceiveroperatingcharacteristiccurve(ROCcurve)
plots the sensitivity against the false-positive rate (one minus the
speciﬁcity)fordifferentcutoffvaluesofadiagnosticmetric,andisa
measure of classiﬁcation performance. The area under the ROC
curve,orAUC,canbeusedtoassessthediagnosticperformanceofa
metric.ArandomclassiﬁerhasAUC = 0.5,andanoptimalclassiﬁer
withperfectsensitivityandspeciﬁcityof100%hasAUC = 1.
The combined metric C0 was deﬁned as the summed log2
expression measured by microarray of hsa-miR-124 and hsa-miR-
219-5p: C0 ≡ [log2(hsa-miR-124 signal) + log2(hsa-miR-219-5p
signal)], and had AUC = 1 when used to identify primary brain
tumors from other primary tumors, but had AUC = 0.8987 when
used to identify brain primary tumors from brain metastases (Fig-
ure S5 in Supplementary Information). The combined metric C1
was deﬁned as the summed log2 expression measured by micro-
array of hsa-miR-9* and hsa-miR-92b: C1 ≡ [log2(hsa-miR-9*
signal) + log2(hsa-miR-92b signal)], and had AUC = 1 when used
to identify primary brain tumors from other primary tumors or
from brain metastases.The calculated values of C0 and C1 for each
samplearelistedinTable S1inSupplementaryInformationonline.
The combined metric CRT was deﬁned as the summed log2
expression levels measured by qRT-PCR data (the Ct values)
of hsa-miR-9 and hsa-miR-92b: CRT ≡ 100 - [Ct(hsa-miR-9)
+ Ct(hsa-miR-92b signal)], had AUC = 1 in the training set data
and one error in the test-set data when used to identify primary
brain tumors from other primary tumors or from brain metastases.
The combined metric CRT* was deﬁned as the summed qRT-PCR Ct
values of hsa-miR-9* and hsa-miR-92b: CRT* ≡ 100 - [Ct(hsa-
miR-9*) + Ct(hsa-miR-92b signal)], had AUC = 1 in the training
set data and one error in the test-set data when used to identify
primary brain tumors from other primary tumors or from brain
metastases. The calculated values of CRT and CRT* for each sample
are listed inTable S2 in Supplementary Information online.
RESULTS
We proﬁled microRNA expression levels on a microarray platform
in 252 tumor samples including 15 brain primary tumor samples,
Table 2. Comparison between microRNA
expression in primary brain tumors and
expression in other primary tumors or
expression in brain metastases, based on
microRNA microarray data. Abbreviation:
AUC = area under curve.
Primary brain vs. Other primary tumors Brain metastases
P-value† fold-change‡ AUC P-value† fold-change‡ AUC
hsa-miR-124 1.4E-54 97.1 0.9975 5.4E-06 12.6 0.8600
hsa-miR-219-5p 9.7E-43 10.0 0.9679 4.1E-09 6.9 0.8840
C0† 1.8E-49 293.0 1.0000 9.0E-09 27.7 0.8987
hsa-miR-128 5.4E-27 9.3 0.9929 4.5E-11 4.2 0.9507
hsa-miR-9* 1.4E-64 31.3 1.0000 9.1E-22 18.9 0.9933
hsa-miR-92b 1.8E-26 7.3 0.9993 2.1E-18 5.8 1.0000
C1† 1.7E-57 205.9 1.0000 3.3E-26 128.7 1.0000
†P-values are calculated on log-signal of microRNAs, and on C0 and C1 (methods), which are in
log-space. Less that 1000 probes were tested, and even after the more severe Bonferroni correc-
tion (multiplying each P-value by ~1000), the P-values remain highly signiﬁcant.
‡The fold change is calculated by dividing the median signal in brain primary tumors by the median
signal in other tissues.
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various tissue origins (see summary in Table 1 and detail in
Table S1 in Supporting Information online). We compared the
brain primary tumor samples to the other primary tumor samples
and to samples of brain-located metastases (Table 2 and methods).
Hsa-miR-124, which is highly speciﬁc to the nervous system (14),
displayed the greatest disparity in expression when comparing
brain primary tumors to other primary tumors, with a fold-change
of ~100 (P-value = 5.1e-57, AUC = 0.9976, see Table 2 and
Methods). A combination of hsa-miR-124 and hsa-miR-219-5p
(C0, see methods) could be used to distinguish brain primary
tumors from non-brain primary tumors with 100% accuracy
(Figure 1A, see Table S1 in Supporting Information for values).
Otherbrain-speciﬁcmicroRNAssuchashsa-miR-128alsoshowed
very strong differential expression between brain primary tumors
and other primary tumors (P-value < 4e-28, AUC = 0.9932, see
Figure S4A in Supporting Information online). In extracting and
proﬁling microRNA from bulk tissue samples, the measured RNA
sample contains RNA from the tumor cells, but also RNA from the
surroundingtissue.Inourstudy,morethan90%ofthesampleshad
a tumor content of at least 50%; nevertheless, a fair amount of
non-tumor cells are present in the specimens. These microRNAs,
whicharehighlyexpressedinnormalbrain(14),werealsofoundat
high levels in RNA extracted from brain metastases (Figure 1A).
This latter effect, ostensibly caused by contamination from the
adjacent normal brain tissue, limits the utility of these microRNAs
to serve as biomarkers for differentiating between brain primary
tumors and brain-located metastases (AUC of 0.85~0.95, see
Table 2 and Figure S5).
We observed that in addition to the aforementioned microRNAs
(hsa-miR-124, hsa-miR-219-5p and hsa-miR-128), hsa-miR-9*
and hsa-miR-92b are expressed speciﬁcally in brain tumors and
not expressed in other tumor types (Figure 1B and Table 2:
AUC > 0.99). Importantly, these two microRNAs also differentiate
accurately between brain primary tumors and metastatic tumors
located in the brain (P-value < 3e-18, AUC > 0.99 for each).
Indeed, using a combination of hsa-miR-9* and hsa-miR-92b
expression (C1, see methods) it is possible to distinguish brain
primarytumorsamplesfromallothersampleswith100%accuracy
in the microarray data (Figure 1B and Table 2). A simple decision
rule,“classifyasprimarybraintumorifC1 > 19,classifyasotherif
C1  19,” identiﬁes correctly all samples. A more conservative
classiﬁer can be deﬁned by allowing a margin for uncertainty of
factor 2 above or below the threshold (equivalent to one cycle in
qRT-PCR measurements).The classiﬁcation rule “classify as brain
primary if C1 > 20, classify as other if C1 < 18, leave unidentiﬁed if
18  C1 20” leaves only two samples out of 252 (<1%) as
unclassiﬁed (Figure 1B, see Table S1), and classiﬁes correctly all
other samples.
To validate these ﬁndings, we proﬁled 14 of these samples and
33 additional samples by qRT-PCR (Table S2), for four potential
biomarkers: hsa-miR-124, hsa-miR-9, hsa-miR-9* and hsa-miR-
92b (Table 3), and two controls: hsa-miR-24, which was found to
be relatively constantly expressed in the microarray data, and
snRNA U6. These microRNAs showed the same pattern as
observed in the microarray data (Table 3). Hsa-miR-124 showed
strong expression in the brain primary tumors, weak expression
in other primary tumors and intermediate expression in the
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Figure 1. Identiﬁcation of metastatic brain tumors using microRNA
microarray data. A. Expression levels of hsa-miR-124 and hsa-miR-
219-5p in 15 brain primary tumors (blue/cyan squares), 187 primary
tumors from other tissues (black/yellow diamonds) and 50 brain
metastases originating from various tissues (green circles). Expression
levels of hsa-miR-124 and hsa-miR-219-5p are higher in brain primary
tumors compared to primary tumors from other tissues. The solid line
marks the line where C0 ≡ [log2(hsa-miR-124) + log2(hsa-miR-219-
5p)] = 16.8, and provides perfect separation between brain primary and
other primary tumors. The expression levels of hsa-miR-124 and hsa-
miR-219-5p in metastatic samples span a wide range on both sides of
the separating line. B. Expression levels of hsa-miR-9* and hsa-miR-92b
in the same samples. Expression levels of these microRNAs are high in
brain primary tumors but are low in all other samples. The solid line
marks the line where C1 ≡ [log2(hsa-miR-9*) + log2(hsa-miR-92b)] = 19,
and provides perfect separation between brain primary tumors and other
samples, including other primary tumors and metastases to the brain.
The dashed lines mark a conﬁdence range of factor 2 above or below,
C1 = 20 (upper line) and C1 = 18 (lower line). Only two of the samples
(<1%) fall within the low-conﬁdence range.
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date for identifying metastatic tumors to the brain. On the other
hand, hsa-miR-9, hsa-miR-9* and hsa-miR-92b showed speciﬁc
strong expression in primary brain tumors with lower expression in
other tumors and in metastases to the brain (Figure 2), with signiﬁ-
cant differences and strong separability between brain primary
tumors and brain metastases (Table 3).
We deﬁned combinations of hsa-miR-92b with either hsa-miR-9
(CRT) or with hsa-miR-9* (CRT*) by summing their qRT-PCR Ct
values (see Methods).We selected a threshold for classiﬁcation for
each combination using half of the samples as a training set. We
thentestedtheclassiﬁcationaccuracyonthesecondhalfofthedata
set that was used as a test-set. The classiﬁcations on the test-set
were near perfect with one outlier of 23 samples, reaching 100%
accuracy in identifying non-brain primary tumors from brain
primarytumors,and88%sensitivitywith100%speciﬁcityiniden-
tifyingmetastaticbraintumorsfrombrainprimarytumors,forboth
CRT* (Figure 2B) and CRT (Table S2). Indeed, these combinations
show signiﬁcant differences in expression that can be used to clas-
sify primary from metastatic brain tumors (Table 3).
According to these data, we propose that hsa-miR-9/9* and hsa-
miR-92b, and their combination, represent new biomarkers that
canbeusedtoclassifybrainmalignancies—primaryvs.secondary.
Hsa-miR-92b and hsa-miR-9/9* were reported previously to be
expressed in brain tumors and in cell lines derived from brain
tumors (14) and were documented to be expressed speciﬁcally in
Table 3. Comparison between microRNA
expression in primary brain tumors and
expression in other primary tumors or
expression in brain metastases, based on
microRNA qRT-PCR data. Abbreviation:
AUC = area under curve.
Primary brain vs. Other primary tumors Brain metastases
P-value† fold-change‡ AUC P-value† fold-change‡ AUC
hsa-miR-124 4.7E-9 2144 1.0000 1.4E-4 48 0.8633
hsa-miR-9 2.3E-11 17 648 1.0000 2.0E-11 543 0.9833
hsa-miR-9* 1.5E-11 1887 1.0000 1.4E-12 415 0.9922
hsa-miR-92b 1.7E-6 16 0.9542 7.2E-7 8 0.9219
C
RT 1.1E-10 2.9E+5 1.0000 7.7E-12 9993 0.9961
C
RT* 2.8E-10 11 868 1.0000 6.4E-12 2428 1.0000
†P-values are calculated on measured Ct values and on C
RT and C
RT* (methods), which are in
log-space. Here only the listed four potential biomarkers and two combinations were tested, and no
correction for multiple hypothesis testing is needed.
‡The fold change is calculated by converting the data to linear space (by taking the exponent base 2)
and dividing the median signal in brain primary tumors by the median signal in other tissues.
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Figure 2. Identiﬁcation of metastatic brain tumors using microRNA qRT-
PCR data. A. Expression levels (50-Ct) of hsa-miR-124 and hsa-miR-9 in
16 brain primary tumors (blue/cyan squares), 15 primary tumors from
other tissues (black/yellow diamonds) and 16 brain metastases originat-
ing from various tissues (green circles). Expression levels of hsa-miR-
124 and hsa-miR-9 are higher in brain primary tumors compared to
primary tumors from other tissues. The expression levels of hsa-miR-
124 in metastatic samples span a wide range and are more similar to
brain primary tumors; the expression levels of hsa-miR-9 in metastatic
samples are more similar to the non-brain primary tumors. B. Expression
levels (50-Ct) of hsa-miR-9* and hsa-miR-92b in the same samples.
Expression levels of these microRNAs are high in brain primary tumors
and lower in all other samples. The solid line marks C
RT* ≡ 100-[Ct(hsa-
miR-9*) + Ct(hsa-miR-92b)] = 39.9, a threshold that was ﬁt to the training
set half of the data. The test-set samples (symbols with red outline)
were accurately classiﬁed by this threshold, with one outlier. Data points
with Ct larger than 40 are shown with Ct = 40, at (50-Ct) = 10.
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hsa-miR-9/9* appears in the human genome in three places, in
chromosomes 1, 5 and 14, each an identical copy. Hsa-miR-92b is
found on chromosome 1 and differs by only one nucleotide in its
ﬁrst 20 from hsa-miR-92a, a member of the oncogenic miR-17-92
cluster(9).However,theexpressionpatternofhsa-miR-92adidnot
correlate with that of and hsa-miR-92b (Figure S4C) and was
not useful in identiﬁcation between primary and metastatic brain
malignancies.
DISCUSSION
When faced with a neoplastic brain specimen considered most
likely to be a metastasis, a surgical pathologist must always rule
out the possibility that it represents a malignant glioma. As a rule,
certain morphological features aid in the distinction between
secondary and primary neoplasms of the CNS (1). Metastases
retain a cohesive quality as they enlarge, and thus remain demar-
cated from the host tissue, while astrocytic and oligodendroglial
tumors exhibit an inﬁltrative growth pattern, intermingling with
the normal cells of the brain tissue. Additionally, in contrast to
neoplastic glial cells, neoplastic cells of metastatic carcinomas
reveal their epithelial nature by their round or polygonal shape,
distinct cellular borders and lack of processes. Furthermore, the
amount of ﬁbrous tissue in metastatic lesions is typically greater
than in most gliomas, and also, the pattern of necrosis seems to
be different in primary tumors from that seen in metastases.
However, poorly differentiated metastatic carcinoma may be dif-
ﬁcult to distinguish histologically from high-grade astrocytic
malignant neoplasms, particularly on small open or stereotactic
biopsy specimens.
Immunohistochemical studies are often employed to help in
diagnosing brain specimens. One study reported a sensitivity of
100% at a speciﬁcity of 86% for identifying primary glioblastoma
multiforme (GBM) from metastatic carcinoma using immunohis-
tochemical staining for glial ﬁbrillary acidic protein (GFAP), but a
signiﬁcantnumberofthemetastaticcancersarealsostained(17).A
combination of immunostains, including GFAP and cytokeratin
CAM5.2, has been suggested as useful in differentiating poorly
differentiated metastatic carcinoma from GBM (17). However,
GBM may variably stain with cytokeratin immunomarkers, usually
expressed in epithelial tumors. Co-expression of GFAP and cytok-
eratin is frequently found, especially in cases of undifferentiated
and high grade gliomas (8, 16). Therefore, cytokeratin positivity
does not rule out the diagnosis of a glial neoplasm (8). Suggested
workup for the differential diagnosis between primary brain neo-
plasms and poorly differentiated metastatic carcinoma based on
immunohistochemistry, therefore, requires a combination of mul-
tiple factors, and their accuracy in different scenarios has not yet
been established. Regardless of these morphological and immuno-
histological tools, some neoplastic brain specimens still cannot be
deﬁnitively classiﬁed (19). For instance, anaplastic oligodendro-
glioma can be macroscopically discrete and composed of com-
pactly arranged polygonal cells such that it simulates a metastatic
tumor (26). Despite the progress recently made for molecular
evaluationofbraintumors(20,24,29),notmuchdatawasachieved
for the molecular differential diagnosis between primary and meta-
static tumors in the brain.
In this study, we present a new diagnostic tool to aid in the
differentiation between primary and secondary neoplasms of the
CNS: the combined expression of two speciﬁc microRNAs, which
serves as a novel “brain primary tumor” biomarker.
To ﬁnd microRNA biomarkers that classify brain tumors, we
compared microRNA expression proﬁles of brain primary tumors,
non-brain primary tumors and brain metastases. Initial analyses
identiﬁed microRNAs, such as hsa-miR-124, that are signiﬁcantly
over-expressed in brain primary tumors compared to non-brain
primary tumors, and thus appear to distinguish brain tumors from
non-brain tumors (Figure 1A). However, many of these micro-
RNAs are highly expressed in normal brain tissue. Inevitably,
during biopsy procedures, signiﬁcant amounts of normal tissue are
excised along with cancerous tissue. In our samples, the tumor
content was greater than or equal to 50% in more than 90% of the
samples.Nevertheless,asinmoststudiesofexpressionproﬁlingon
tissue samples, a fair amount of non-tumor cells are present in the
specimens.Thus,brain-speciﬁcmicroRNAs,suchashsa-miR-124,
can be found variously in tissue specimens containing brain
metastases, and their expression levels measured in bulk tissue
samples do not allow discrimination between brain primary tumors
and metastases located in the brain.
Further analyses, which included a substantial set of 50 brain
metastasis samples, delineated a subset of microRNAs that are
expressed speciﬁcally in brain primary tumors, but importantly,
neither in non-brain primary tumors nor in brain-located
metastases. Speciﬁcally, we found that hsa-miR-92b and hsa-miR-
9/9* are very signiﬁcantly and strongly over-expressed in samples
of primary brain tumors, but not in samples of metastatic tumors to
the brain. These bulk samples contain surrounding tissue, and it
cannot be ruled out at this stage that a fraction of the over-
expressed microRNAs may be derived from non-neoplastic glial
cells in the surrounding tissue, in which this expression is speciﬁc
toreactivecellssurroundingprimarytumorsonly.Regardlessofits
biological origin, the speciﬁc over-expression of these microRNAs
in samples from brain primary tumors provides important diagnos-
tic information. The combined expression levels of hsa-miR-92b
and hsa-miR-9/9* allow discrimination between brain primary
tumorsandmetastaseslocatedinthebrainwithveryhighaccuracy,
and thus represent a potential biomarker for the identiﬁcation of
brain primary tumors.
Notably, hsa-miR-92b and hsa-miR-9/9* were reported previ-
ously to be over-expressed in neuronal-speciﬁc stem cells and to
exhibit dynamic expression patterns in the developing brain (12,
13, 32, 34). Thus, it appears that elevated expression of these
microRNAs is a feature common to brain stem cells and brain
tumorcells.Whethercancerouscellsoriginatefromabnormalstem
cells or represent de-differentiated somatic cells is a hotly debated
issue (4, 31). In any case, our data reinforce the enigmatic associa-
tion between pluripotency and tumorigenesis. Further research
should elucidate the function of these microRNAs in the brain and
their roles in brain cancer.
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SUPPLEMENTARY MATERIAL
The following supplementary material is available for this article:
Figure S1. A. RNA was extracted and proﬁled (4 mg total
RNA) from a mouse liver sample, which was either preserved as
fresh frozen (y-axis) or formalin-ﬁxed, parafﬁn-embedded (FFPE)
(x-axis). Overall correlation of expressions was 0.9. Similar results
wereobtainedforRNAextractedfromlung.B.Similarresultswere
obtained when comparing microRNA expression extracted from
FFPE sample (x-axis) to the RNA extracted from formalin-ﬁxed
sample(y-axis).Overallcorrelationofexpressionswas0.9.Similar
results were obtained for RNA extracted from lung.We next exam-
ined the difference in the level of microRNA expression in tissues
(liver and lung) preserved at different time points, immediate, 1 h
and 5 h post-operation.The microRNA fraction in the lung was not
affected even when kept non-ﬁxed for 5 h. Delaying ﬁxation of
a liver sample by 1 h had no signiﬁcant change on the microRNA
fraction, but the microRNA fraction was decreased approximately
twofoldwhentheliversamplewaskeptnon-ﬁxedfor5 h,reﬂecting
the high content of nucleases in liver tissue (data not shown).
Figure S2. MicroRNA stability in formalin-ﬁxed, parafﬁn-
embedded (FFPE) archival samples of different ages: total RNA
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2–11 years) and hybridized to the miRdicator™ microarray. Each
bar in the graph depicts the overall microRNA expression corre-
lation (Pearson correlation coefﬁcient) between a single sample
(age appearing on the x-axis), and the newest sample (age 2
years). The high correlation (mostly above 0.9) indicates the
highly preserved fraction of microRNA in parafﬁn blocks even
after many years.
Figure S3. A. Microarray reproducibility: 3 mg of placenta
RNA (Ambion) was repeatedly (seven times) labeled and hybrid-
ized to the microarray. For >200 highly expressed microRNAs
(sorted from top to bottom by mean expression level), each
column depicts the expression in one repeat. For each pair of
repeats, the Pearson correlation coefﬁcient was computed, result-
ing in an overall mean correlation coefﬁcient of 0.99. B. Micro-
array sensitivity and dynamic range: four synthetic short RNAs,
22 nt long, were spiked in different amounts into 3 mg of placenta
total RNA, labeled and hybridized to the array. Each line corre-
sponds to one of the spike-ins. The lowest sensitivity was found
to be 0.1 fmole with a linear dynamic range of about three orders
of magnitude. C. Microarray speciﬁcity: synthetic RNAs of hsa-
let-7a, c and d were spiked into non-relevant background material
(high molecular weight RNA extracted from HeLa cell line,
which shows no hybridization background when hybridized to the
microarray, data not shown) and hybridized to the miRdicator™
microarray. The table depicts the probe signals of the let-7 family
in response to the spiked-in synthetic RNAs (columns), normal-
ized by the signal of the probe corresponding to the synthetic
RNA. Speciﬁcity of about 10-fold in the signal level between
let-7a and let-7c was demonstrated, representing the level of
speciﬁcity for a single nucleotide mismatch. D. Tissue speciﬁcity:
3–5 mg of total RNA extracted from liver and testis formalin-
ﬁxed, parafﬁn-embedded samples were labeled and hybridized
to the miRdicator™ microarray, identifying tissue speciﬁc
microRNA expression proﬁles such as hsa-miR-122a in the liver
and hsa-miR-372 and hsa-miR-373 in the testis tissue.
Figure S4. Expression levels of microRNA (microarray data)
in 15 primary brain tumors (blue/cyan squares), 187 primary
tumors from other tissues (black/yellow diamonds) and 50 brain
metastases from various tissue origins (green circles). A. Hsa-
miR-128hashighexpressionlevelsinbrainprimarytumors,lowin
other primary tumors and intermediate in brain metastasis samples
(see Table 2). In contrast to hsa-miR-128, hsa-miR-92b is speciﬁ-
cally expressed in brain primary tumors, and is lower in primary
tumors from other tissues and in their metastases to the brain.
B. Hsa-miR-124 has high expression levels in brain primary
tumors, low in other primary tumors, and its expression levels in
RNA extracted from brain metastasis samples spans a wide range.
Incontrasttohsa-miR-124,hsa-miR-9*isspeciﬁcallyexpressedin
brain primary tumors, and is lower in primary tumors from other
tissuesandintheirbrainmetastases.C.Expressionofhsa-miR-92a
did not correlate with expression of hsa-miR-92b and was not
useful for identiﬁcation between primary and metastatic brain
malignancies.
Figure S5. The receiver operating characteristic curve (ROC
curve) plots the sensitivity against the false-positive rate (one
minus the speciﬁcity) for different cutoff values of a diagnostic
metric, and is a measure of classiﬁcation performance. The area
under the ROC curve [area under curve(AUC)] can be used to
assesthediagnosticperformanceofmetric.Arandomclassiﬁerhas
AUC = 0.5, and an optimal classiﬁer with perfect sensitivity and
speciﬁcity of 100% hasAUC = 1. A.The sorted values of C0 for 15
samplesofbrainprimarytumors(bluesquares)and187samplesof
non-brain primary tumors (red circles). The dashed line shows
C0 = 16.8, which perfectly separates these two sets of samples
(sensitivity = speciﬁcity = 100%). B. The ROC curve for C0 in
these samples, which has AUC = 1. C. The sorted values of C0 for
15 samples of brain primary tumors (blue squares) and 50 samples
of brain metastases (red circles).The dashed line shows C0 = 16.8,
which misclassiﬁes 20 of the 50 metastasis samples (sensitiv-
ity = 60%, speciﬁcity = 100%). D. The ROC curve for C0 in these
samples, which hasAUC = 0.8987.
Table S1. Details for the 252 samples measured by microarray,
expression levels of microRNAs used in the study, and combined
metrics C0 and C1.
Table S2. Details for the 47 samples measured by qRT-PCR,
expression levels of microRNAs used in the study, and combined
metrics CRT and CRT*.
This material is available as part of the online article from:
http://www.blackwellsynergy.com
Please note: Blackwell Publishing is not responsible for the
content or functionality of any supplementary materials supplied
by the authors.Any queries (other than missing material) should be
directed to the corresponding author for the article.
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